JMJD7-PLA2G4B: A Potential Drug Target Or Biomarker (G8681)

Target Name: JMJD7-PLA2G4B

NCBI ID: G8681

JMJD7-PLA2G4B

JMJD7-PLA2G4B: A Potential Drug Target Or Biomarker

Cytosolic phospholipase A2 (PLA2) is a protein that is expressed in various cell types of the body, including platelets, macrophages, and endothelial cells. It is involved in the regulation of cellular signaling pathways, and is a potential drug target or biomarker for various diseases. One of the isoforms of PLA2, JMJD7-PLA2G4B, has been identified as a potential drug target or biomarker and is currently under investigation for its potential therapeutic uses.

JMJD7-PLA2G4B and its function

JMJD7-PLA2G4B is a 21-kDa protein that is expressed in human platelets and other cell types. It is a potent phospholipase A2 (PLA2) activator, and its activity can be blocked by inhibitors of PLA2. The JMJD7-PLA2G4B gene is located on chromosome 12q22 and has been shown to be associated with platelet function and platelet aggregation.

PLA2 is a key signaling molecule that is involved in various cellular signaling pathways. It plays a role in the regulation of cell adhesion, migration, and differentiation, and is involved in the development and maintenance of tissues and organs. PLA2 also plays a role in the regulation of inflammation and immune responses.

JMJD7-PLA2G4B has been shown to be involved in the regulation of PLA2 activity in various cell types. For example, it has been shown to enhance the activity of PLA2 in platelets, and to inhibit the activity of PLA2 in macrophages. These effects on PLA2 activity suggest that JMJD7-PLA2G4B may be a potential drug target or biomarker for platelet-related diseases.

Drug targeting JMJD7-PLA2G4B

Drug targeting JMJD7-PLA2G4B is a promising approach for the development of new treatments for various diseases, including cardiovascular disease, cancer, and autoimmune disorders.

One potential mechanism by which JMJD7-PLA2G4B could be targeted is through its role in platelet function. Platelets play a critical role in the regulation of blood clot formation, and are involved in the development of cardiovascular disease. JMJD7-PLA2G4B has been shown to enhance the activity of PLA2 in platelets, which may contribute to the regulation of platelet function.

Another potential mechanism by which JMJD7-PLA2G4B could be targeted is through its role in cancer progression. JMJD7-PLA2G4B has been shown to be involved in the regulation of cell adhesion and migration, which are critical processes that contribute to cancer cell progression.

In conclusion

JMJD7-PLA2G4B is a protein that is involved in various cellular signaling pathways and has been shown to play a role in the regulation of PLA2 activity in various cell types. Its potential as a drug target or biomarker for various diseases makes it an attractive target for future research. Further studies are needed to fully understand the role of JMJD7-PLA2G4B in cellular signaling pathways and its potential as a drug target or biomarker.

Protein Name: JMJD7-PLA2G4B Readthrough

The "JMJD7-PLA2G4B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about JMJD7-PLA2G4B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets